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Previous studies from this laboratory showed that the action of Osteogenic Protein-1 (OP-1, BMP-7) on osteoblastic cell differentiation could
be enhanced by other protein factors, such as Insulin-like Growth Factor (IGF)-I. In the present study, we examined the effects of co-transfection
with a combination of the OP-1 and the IGF-I gene on osteoblastic cell differentiation. The results first showed that fetal rat calvaria (FRC) cells
transfected with the OP-1 gene under the control of the cytomegalovirus (CMV) promoter showed substantial production of the OP-1 protein.
Transfected FRC cells also showed a DNA concentration-dependent increase in alkaline phosphatase (AP) activity, an osteoblastic cell
differentiation marker. Von Kossa-positive nodules, a hallmark of bone formation in long-term cultures of bone-derived cells, were also observed
in the transfected cells after 26 days in culture, whereas none were observed in control cells. Co-transfection of FRC cells with the combination of
the OP-1 and the IGF-I gene resulted in a synergistic stimulation of AP activity. The increase was DNA dose-dependent. The current data show
that transfection of OP-1 gene into osteoblastic cells stimulates osteoblastic cell differentiation in vitro. The study further demonstrates the
feasibility of employing gene transfer of a second gene in combination with an OP-1 vector to synergistically enhance OP-1 activity.
D 2005 Elsevier B.V. All rights reserved.Keywords: Bone morphogenetic protein; Osteogenic protein-1; IGF-I; Synergy; Cell differentiation; Osteoblast; Co-expression1. Introduction
During osteoblastic cell differentiation, the expression of a
number of factors, including growth factors and regulators are
activated or repressed in a defined temporal and spatial
manner [1–4]. Osteogenic Protein-1 (OP-1, also known as
BMP-7), a member of the bone morphogenetic protein (BMP)
family that belongs to the Transforming Growth Factor
(TGF)-h superfamily [5–9], induces formation of new bone
and cartilage in vivo [10–12]. In the differentiation process,
OP-1 regulates the expression of a variety of molecular events
culminating in bone formation [13–22]. Several numbers of
the molecules involved in the differentiation process have
been identified and characterized, but many remained to be
identified. Knowledge of the functional relationship between
these molecules and OP-1 should provide important insights
into OP-1 action in osteogenesis.0167-4889/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2005.11.001
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E-mail address: yehl@uthscsa.edu (L.-C.C. Yeh).Several protein factors have been shown to enhance OP-1
action. For example, exogenous Insulin-like Growth Factor
(IGF)-I synergistically enhances alkaline phosphatase (AP)
activity as well as the rate and the extent of mineralized bone
nodule formation in OP-1-treated FRC cells [23]. Exogenous
Interleukin (IL)-6 together with its soluble receptor also
enhances OP-1 activity [24]. Several osteotropic factors, e.g.
human growth hormone, prostaglandin E2, and parathyroid
hormone also enhance OP-1 activity to varying degrees in vitro
[25]. Bone morphogenetic protein (BMP)-2 [26] and cartilage-
derived morphogenic protein (CDMP)-1 [27] have recently
been shown to enhance OP-1-induced osteoblastic cell
differentiation. A recent report also showed that combined
transduction with adenovirus expressing BMP-2 or -4 plus
BMP-7 resulted in a synergistic stimulation of osteoblastic cell
differentiation [28]. The synergy is presumably due to the
formation BMP-2/7 and 4/7 heterodimers which have been
reported previously to be more active than the homodimers.
Clinical studies have demonstrated the utility of OP-1 in a
variety of orthopedic illnesses, such as fracture healing. Gene
therapy is an attractive approach to express these proteinsta 1763 (2006) 57 – 63
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systemic delivery with tissue-specific expression seems possi-
ble. The present study was designed to examine the effective-
ness of gene transfer of a second gene in combination with an
OP-1-expressing vector to produce an enhancement of the
osteoinductive activity of OP-1 in vivo. We selected IGF-I as
our test model for the second gene. The rationale is that we
previously demonstrated that treatment of FRC cells with IGF-I
protein synergistically enhances OP-1 activity. Moreover, the
effects of IGF-I protein alone on bone cells are well studied.
However, the effectiveness of co-transfection with the combi-
nation of the OP-1 gene and the IGF-I gene has not been
experimentally demonstrated. Accordingly, we examined the
effects of co-transfection with the OP-1 gene and the IGF-I
gene on the differentiation of FRC cells.
2. Materials and methods
2.1. Construction of plasmids
Plasmid pW24 (10.35 kb) that contains the coding sequence for OP-1
including the pre–pro region under the control of the cytomegalovirus (CMV)
promoter was a gift from Stryker Biotech (Hopkinton, MA). A brief schematic
of pW24 is shown in Fig. 1A. To generate the control plasmid pCMV, pW24
was digested with restriction enzyme XhoI to remove the OP-1 coding
sequence, purified on agarose gels, and re-ligated to produce the resultant 9.1
kb plasmid. Plasmid pIGF-I (or pI, 5.88 kb) contains a 740-bp human IGF-I
sequence inserted into the EcoRI/EcoRV site of pA (pcDNA4/TO/myc-HisA,
5.14 kb, Invitrogene, Carlsbad, CA) (Fig. 1B). The IGF-I gene was under the
control of the CMV promoter. The 740 bp IGF-I sequence was obtained by
digestion of pT7T3D-Pac (IMAGE ID 502856 from ATCC, Manassas, VA)
with EcoRI/DraI. The sequence contained the full-length human IGF-I gene
(from 159 to +574, +1 being the translation start site). The base sequence of
all the resultant DNA constructs was determined by double-strand sequencing.Fig. 1. (A) A schematic of pW24 plasmid. The OP-1 gene was inserted into the
pMAM-neo vector (Clontech, Inc. Palo Alto, CA) at the SmaI and BamHI sites.
The OP-1 gene is under the control of the CMV promoter. (B) A schematic of
pIGF-I plasmid. The IGF-I gene was inserted into the pcDNA4/TO/myc-HisA
vector (Invitrogene, Carlsbad, CA) at the EcoRI and EcoRV sites. The IGF-I
gene is under the control of the CMV promoter.All plasmid DNAs were isolated using the Qiagen’s plasmid Maxi kit
(Valencia, CA) and checked for purity on 1% agarose gels. Only the ultrapure
DNA prep was used for studies reported herein.
2.2. Fetal rat calvaria cell culture
Animals were handled and killed following the procedures approved by the
Institutional Animal Care and Use Committee of The University of Texas
Health Science Center at San Antonio, TX. Primary osteoblastic cell cultures
were prepared by subjecting the calvarium from the fetus of timed pregnant
Sprague–Dawley rats to sequential digestion with trypsin/collagenase as
described previously [19].
2.3. Transfection
Transfection studies were carried out using FuGene6 (Roche, Indianapo-
lis, IN) following the manufacturer’s recommendation. Briefly, cells were
plated at a density of 2.5104/cm2 in complete aMEM containing 10% FBS
and antibiotics (100 U/ml penicillin and 100 Ag/ml of streptomycin sulfate).
Cells were incubated at 37 -C with 5% CO2 until confluent. Confluent cells
were transfected using FuGene6 (3 Al/Ag DNA) with either pW24, pIGF, or
pW24+pIGF under conditions as indicated in each figure legend. For the
determination of effects of co-transfection, confluent FRC cultures were
treated with 5 Ag/ml of pW24 plus varying concentrations of pI (0, 1, 2, 5,
10, and 20 Ag/ml). As controls, confluent cultures were mock transfected,
transfected with pI alone (2 and 10 Ag/ml) or the control plasmid pA (20 Ag/
ml). After 48 h of recovery in complete aMEM and 10% FBS, total AP
activity in lysates of cell layers was measured.
2.4. Western blot analysis
To determine OP-1 expression in transfected cultures, confluent cultures
were treated with no DNA, pCMV control DNA (1 Ag/ml), pCMV (1 Ag/ml)
plus pA control DNA (1 Ag/ml), pW24 (1 Ag/ml), or pW24 (1 Ag/ml) plus pI
(0.5 Ag/ml). Cells were allowed to recover in complete aMEM media
containing 10% FBS and antibiotics for 48 h. Total cellular proteins were
isolated from cell lysate and the protein concentration was measured according
to the method of Bradford using BSA as a standard. Equal amounts of total
protein from the different samples were loaded onto a reducing, denaturing,
SDS-containing polyacrylamide gel (12%). After electrophoresis, proteins were
transferred onto a nitrocellulose membrane using a semi-dry Trans-Blot transfer
system (Bio-Rad, Hercules, CA). Membranes were incubated in 20 mM Tris,
pH 7.6, 137 nM NaCl, 0.1% Tween-20, and 5% nonfat dry milk and probed
with an anti-OP-1 polyclonal antibody (Stryker Biotech). The antibody was
previously tested to react with the mature form of OP-1 and not the precursor of
OP-1. Nor would it react with activin, TGF-h, or BMP-2, -4, -5, and -6 (data
not shown). The antigen–antibody complex was detected with anti-rabbit IgG
conjugated with Horseradish peroxidase (HRP) and the Supersignal ECL kit
(Pierce, Rockford, IL) following the manufacturer’s instruction.
2.5. Alkaline phosphatase (AP) activity assay
To determine the AP activity in FRC cells transfected with varying
concentration (0–10 Ag/ml) of pW24 alone, confluent cells grown in 48-well
plates were transfected for 4 h and grown in complete aMEM plus 10% FBS as
described above. After 24 and 48 h post-transfection, cells were rinsed with
PBS and lysed by sonication in 0.1% Triton X-100 in PBS (100 Al/well) for 5
min at room temperature. Total AP activity in the lysate of cell layers was
measured using a commercial assay kit (Sigma, St. Louis, MO) as described
previously [19]. Total protein level was measured at 590 nm according to the
method of Bradford with BSA as a standard. AP activity was expressed as
nanomoles of p-nitrophenol liberated per microgram of total cellular protein. To
determine effects of exogenous IGF-I on the AP activity in pW24 transfected
FRC cells, confluent transfected cells grown in complete aMEM media in 48-
well plates were treated with varying concentrations (0–37.5 ng/ml) of IGF-I.
After 48 h, cells were processed and total AP activity in cell layer lysates was
measured as described above.
Fig. 2. Western blot analysis of OP-1 expression in FRC cells transfected with
pW24. Twenty-five Ag of total protein from lysates of transfected cell layers
were resolved on a 12% SDS-containing, reducing, and denaturing polyacryl-
amide gel. After transfer of the proteins onto a nitrocellulose membrane, the
proteins were analyzed with the OP-1 antibody and the antibody–antigen
complex was detected with anti-rabbit IgG-HRP conjugate. The signals were
developed with an ECL kit. Lane 1: no DNA control. Lane 2: pCMV control
DNA. Lane 3: pCMV plus pA control DNAs. Lane 4: pW24 (1 Ag/ml). Lane 5:
pW24 plus pI (0.5 Ag/ml). Lane 6: recombinant OP-1 protein control. Positions
of molecular weight standards are indicated by arrows on the right hand of the
blot. (B) AP activity in pW24 transfected FRC cells. Total AP activity in lysates
of transfected cell layers was measured after 24 (0) and 48 (˝) h post-
transfection. AP activity was expressed as nanomoles of p-nitrophenol
liberated/Ag of total protein. The relative AP activity is the activity normalized
to that in cells treated with 0.1 Ag/ml DNA (as 1). Values represent the
meanTS.E.M. of two determinations on two independent experiments using two
different FRC cell preparations. Each determination involved 6 replicate
samples from the same experiments. (*), P0.05, compared to the 0.1 Ag/ml
DNA value.
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For nodule formation measurement, confluent FRC cells grown in 6-well
plates were transfected with 0.4 or 0.8 Ag/ml of pW24 without antibiotics for 4
h. Transfected FRC cells were grown in complete aMEM containing 10% FBS
in the presence of ascorbic acid (100 Ag/ml), h-glycerol phosphate (5 mM) and
Neomycin (250 Ag/ml). Media were changed every 3 days. Progress of nodule
formation was monitored and images were captured with an Olympus CK2
inverted microscope equipped with a CCD camera on day 26 and 32 post-
transfection. At the end of the experiment, cultures were stained for von Kossa
positive nodules as described previously [23].
2.7. Statistical analysis
Data are presented as the meanTS.E.M. Statistical differences between
means were determined by one-way ANOVA followed by post hoc Least
Significant Difference Multiple Comparisons with the use of the SIMSTAT3
software package (Normand Peladeau, Provalis Research, Montreal, Canada).
Probability values of 0.05 indicate a significant difference.
3. Results
3.1. FRC cell transfected with pW24, a plasmid that
contains the OP-1 coding sequence, showed production of
OP-1 protein
Western blot analysis, with an OP-1-specific antibody,
revealed that OP-1 protein was not detectable in the Mock-
transfected cells (Fig. 2A, lane 1), in cells transfected with the
empty plasmid pCMV (lane 2), or with both empty plasmids
pCMV and pA (lane 3). Upon transfection with pW24, the
resultant cells expressed an immuno-positive protein with an
approximate molecular weight of 16 kDa, a value consistent
with that of the monomer of OP-1. The anti-OP-1 antibody was
previously reported to only recognize the monomeric, mature
form and not the precursor form of OP-1 (Fig. 2A, lane 4). A
positive control with the recombinant OP-1 protein showing
that the antibody recognized the mature form of OP-1 is
included (Fig. 2A, lane 6).
3.2. Cells transfected with pW24 expressed elevated
osteoblastic cell characteristics
Previous studies show that osteoblastic cells treated with
the OP-1 protein undergo cell differentiation as measured by
increased expression of characteristic biochemical markers,
such as AP activity [19]. Fig. 2B shows that cells transfected
with pW24 exhibited a time- and DNA dose-dependent
stimulation in AP activity. After 24 h, cells transfected with
10 Ag/ml pW24 showed an 8-fold increase in AP activity,
compared to that transfected with 0.1 Ag/ml DNA. After 48
h, the AP activity in cells transfected with all the different
concentrations of pW24 increased by 4- to 5.5-fold beyond
those after 24 h, except at the highest concentration tested.
At 10 Ag/ml of pW24, the AP activity was stimulated by
about 10-fold (compared to that transfected with 0.1 Ag/ml
DNA).
To examine longer-term effects of pW24, cells were
transfected with 0.4 or 0.8 Ag/ml pW24 and cultured in the
presence of 250 Ag/ml neomycin. No mineralized noduleswere detectable in the mock-transfected cultures after 26 or 32
days (Fig. 3A). Nodule formation was observed in the pW24-
transfected cultures and was time- and DNA dose-dependent
(Fig. 3). Clone 1 from the culture treated with 0.4 Ag/ml and
clone 2 from that with 0.8 Ag/ml were selected for longer-term
monitoring. After 26 days, clones 1 and 2 showed nodule
formation (left column, Fig. 3B and 3C, respectively). Signs of
initial mineralization were detected in Clone 1, but significant
mineralization was detected in Clone 2. By 32 days, the extent
of mineralization in the nodule of clone 1 increased
significantly (Fig. 3B, right column). The size of the nodule
and the extent of mineralization of clone 2 appeared
unchanged to any significant extent (Fig. 3C, right column),
compared to day 26. The reason for this is not clear; perhaps
the rate of mineralization slowed down and the change was not
detectable.
Fig. 3. Nodule formation in FRC cells transfected with pW24. Confluent FRC cells in 6-well plates were transfected with pW24 (0.4 or 0.8 Ag/ml) using FuGene6 (3
Al/Ag DNA). Cells were cultured in complete aMEM containing 10% FBS, ascorbic acid, h-glycerol phosphate, and Neomycin. Media were changed every 3 days.
Progress of nodule formation was monitored periodically and the images were captured using an Olympus CK2 inverted microscope 26 and 32 days post-
transfection. (A) Representative images of mock-transfected controls. (B) Images showing the progression of clone 1 which was produced by transfection with 0.4
Ag/ml of pW24. (C) Images showing the progression of clone 2 which was produced by transfection with 0.8 Ag/ml of pW24.
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transfected with pW24
Previously, we have shown that simultaneous treatment of
FRC cells with OP-1 and IGF-I proteins results in a
synergistic enhancement of the OP-1 action in stimulating
cell differentiation [23]. In the present study, we examined
whether exogenous IGF-I exerts any effect on the AP activity
of pW24-transfected FRC cells. First, to assess possible
effects of the transfection procedure on the capability of these
cells to respond to OP-1, mock-transfected cells were treated
with IGF-I, OP-1 or OP-1+IGF-I, and the AP activity was
measured. The concentration of OP-1 and IGF-I selected for
the experiment was previously determined to be optimal [23].
IGF-I alone did not stimulate AP activity (Fig. 4A, lane 2vs. 1). OP-1 stimulated AP activity by an average of about
1.6-fold, compared to the vehicle control (Fig. 4A, lane 3 vs. 1).
The extent of stimulation was lower than expected but was
reproducible. Exogenous IGF-I further stimulated AP activity in
the pW24-transfected cells by 2.8-fold, compared to the control
(Fig. 4A, lane 4 vs. 1). The extent of stimulation in AP activity in
both cases was less than that usually observed with FRC cells not
subjected to the transfection manipulation [23]. A possible
reason for the lower than expected response may be that these
mock-transfected FRC cells had not completely recovered from
the shock of transfection.
To test the effects of exogenous IGF-I on the pW24-
transfected FRC cells, different concentrations of IGF-I were
added to the media of the transfected cultures, and the total AP
activity was measured after 48 h. Fig. 4B shows that the
Fig. 5. Total AP activity in FRC cells co-transfected with plasmids pW24 and
pI. Confluent FRC cells were co-transfected with 5 Ag/ml of pW24 and
varying concentrations of pI (0, 1, 2, 5, 10, and 20 Ag/ml). After 48 h of
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increasing concentrations of exogenous IGF-I was elevated in
an IGF-I dose-dependent manner (Fig. 4B, lanes 2 to 6 vs. 1).
A maximum stimulation of 1.7-fold above that in cells
transfected with pW24 alone was observed (Fig. 4B, lane 6
vs. 1). Published results showed that IGF-I alone in the
concentration range tested did not stimulate AP activity in FRC
cells [23].
3.4. Co-expression of FRC cells with pW24 and pIGF-I (pI)
resulted in an increased AP activity
The effect of co-transfection of FRC cells with pW24 and
pI, a plasmid containing the IGF-I gene was examined. FRC
cells were transfected with a constant amount of pW24 andFig. 4. (A) Effects of exogenous OP-1 and IGF-I on mock-transfected cells.
Cells were mock transfected and treated for 48 h with IGF-I (25 ng/ml) alone,
OP-1 (200 ng/ml) alone or OP-1 (200 ng/ml) plus IGF-I (25 ng/ml). Total AP
activity in lysates of cell layers was determined. Values were normalized to the
control (=1). (B) Effect of exogenous IGF-I on AP activity in pW24 transfected
FRC cells. FRC cells were transfected first with of 2 Ag/ml pW24. After two
days in complete aMEMmedia for recovery, cultures were treated with varying
concentrations (0–37.5 ng/ml) of IGF-I. Total AP activity in lysates of cell
layers was measured after 48 h. Values were normalized to the pW24
transfected and IGF-I untreated sample (=1). The values represent the
meanTS.E.M. of determinations from two independent experiments, each
involving 6 replicate samples. The two experiments used two different FRC cell
preparations. (*), P0.05, compared to the no treatment control.
recovery in complete media, total AP activity in lysates of cell layers was
measured. Values were normalized to the pW24 only transfected (=1) sample.
The values represent the meanTS.E.M. of determinations from seven
independent experiments, each involving 6 replicate samples. The seven
experiments used 3 separate FRC cell preparations and 3 different pW24 and
pIGF-I plasmid DNA preparations. pA is an empty vector without the IGF-I or
the OP-1 gene. (*), P0.05, compared to the pW24-transfected sample.increasing amounts of pI. After 48 h, the level of OP-1 protein
expression and total AP activity were measured. Fig. 2A (lane
5) showed that the OP-1 expression levels in cells co-
transfected with pW24 plus pI and with pW24 alone were
similar. Fig. 5 shows that the AP activity in cells co-transfected
with pW24 and pI increased as a function of pI concentration
(lanes 5–9 vs. 1). A maximum of 1.9-fold stimulation was
achieved compared to that in cells transfected with pW24 alone
(lane 9 vs. 1). The AP activity in cells transfected with two
different concentrations of pI alone was not significant (lanes 2
and 3). Co-transfection with pW24 and the empty plasmid pA
(vector without the IGF-I gene) did not result in an increase in
AP activity beyond that by pW24 alone (lane 4 vs. 1). These
observations implied that the stimulation of AP activity in the
co-transfected FRC cells was the result of the synergistic action
of endogenous OP-1 and IGF-I proteins produced by the
double-transfected cells. FRC cells co-transfected with the two
empty plasmids, pCMV (vector without the OP-1 gene) and pA
did not show an increase in AP activity (data not shown).
4. Discussion
The current data demonstrate that transfection of calvaria
osteoblastic cells with a plasmid expressing OP-1 gene under
the control of the CMV promoter stimulates expression of
biochemical markers characteristic of differentiating osteoblas-
tic cells in vitro. The study indicates that the transfected cell
had undergone osteoblastic cell differentiation and that the OP-
1 protein produced by the plasmid-coding OP-1 gene stimu-
lated the differentiation process. The data are consistent with
previously reported studies using the OP-1 protein showing
that OP-1 induces expression of osteoblastic cell differentiation
markers in vitro [13,23,29,30]. Our finding is also consistent
with previous studies on a variety of cell types using adenoviral
vectors. For example, C2C12 cells infected with adenovirus
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suggesting that BMP-7 induced C2C12 cells into the osteo-
genic pathway [31]. Chondrocytes infected with a BMP-7
expressing adenovirus showed enhanced matrix synthesis [32].
Implantation into critical-size cranial defects of rabbit perios-
teal cells transduced with the BMP-7 gene resulted in increased
bone repair as revealed by radiographic and histological
measurements [33]. C2C12 cells infected with a BMP-2
expressing adenoviral vector exhibited elevated levels of AP
activity and osteocalcin expression [34]. The AP activity in W-
20-17 stromal cells infected with a BMP-2 expressing
adenovirus was also elevated [35,36]. Pluripotent mesenchy-
mal stem cells infected with BMP-2 expressing adenovirus also
were induced to express osteoblastic markers [37]. The results
indicate that OP-1 (BMP-7) and BMP-2 gene transfer can lead
to osteogenesis of target cells.
The present study shows that significant enhancement of
osteogenic cell differentiation can be accomplished by co-
transfection with an osteogenic protein gene, such as OP-1 and
an enhancer gene, such as IGF-I. Thus, our results further
extend the previous observation regarding synergy between
OP-1 and IGF-I [23]. The previous results were obtained by
treating FRC cells with soluble OP-1 and IGF-I proteins,
whereas the present data were obtained by gene transfer. Taken
together, these results demonstrate that treatments with an
appropriate combination of proteins or of their genes can
produce similar synergistic effects.
In contrast to our finding, Smith et al. [38] reported that
rabbit articular chondrocytes transduced with recombinant
adenovirus carrying the BMP-2 gene showed an approxi-
mately 8-fold increase in proteoglycan synthesis. Transduced
cells carrying the IGF-I gene showed a 2- to 3-fold increase.
However, co-transduction of chondrocytes with adenovirus
carrying both BMP-2 and IGF-I genes resulted in an
additive effect in stimulating proteoglycan synthesis. The
apparent difference in findings between the two studies may
be attributed to the difference in cell types used in these
studies.
Also of interest are two recent studies which show that co-
transfection with two BMP genes can result in an enhanced
osteogenic activity. Zhu et al. [26] showed that combined
BMP-2 and BMP-7 gene transfer of C2C12 and MC3T3-E1
cells enhances the levels of AP activity and osteocalcin
expression in vitro beyond the levels induced by either BMP
alone. Zhao et al. [28] further demonstrated that implantation
of fibroblasts co-transducted with adenovirus vectors expres-
sing BMP-2 and -4 plus BMP-7 into C57BL6 mice resulted in
an enhanced bone formation. Although these studies are similar
to the present study in terms of the resultant synergistic effect
of co-transfection, the reason of synergy is different. In their
studies, the enhancement is believed to be the result of
formation of heterodimers instead of homodimers of BMP.
The heterodimers have previously shown to be more active
than the homodimers. The current study showed that produc-
tion of the plasmid-directed OP-1 was not affected by
exogenous IGF-I. Additionally, previous studies from our
laboratory showed that phosphatidylinositol 3-kinase andmTOR contribute, at least in part, to the synergistic effect of
OP-1 and IGF-I on AP activity in FRC cells [39].
In summary, the present study demonstrates the feasibility
of employing gene transfer of a second gene in combination
with an OP-1 vector to enhance OP-1 activity. Our findings
clearly indicate that co-expression of OP-1 and IGF-I genes led
to accelerated and elevated osteoblastic cell differentiation in
vitro. Whether the combination will enhance bone repair in
vivo will be an important area of experimentation.
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